Table 1 Summary of studies on J147
Author | J147 dose | Time after J147 evaluation | Cell and animal models | Mice age | Evaluated task | Results | Mechanisms | Disease or effect | |
|---|---|---|---|---|---|---|---|---|---|
Chen et al. 2011 [14] | 1, 2, 5 mg/kg | Fed for 7 days | Sprague-Dawley Rat | 7 weeks | NOR | better performance | Reduces soluble Aβ levels, oxidative stress, heat-shock proteins, and inflammation, increases synaptic protein and BDNF expression | AD | |
10–20 mg/kg/day | Fed for 2 weeks | Mice | 6 weeks | Barnes maze, Y-maze and NOL | better performance | ||||
0–20 µM | 24 and 48 h | HT22, PC12, and primary cortical neurons | / | / | / | ||||
Prior et al. 2013 [24] | 10Â mg/kg/day | Fed for 3 months | Mice | 20 months | Two-day water maze, EPM, fear-conditioning assay, and Y maze | better performance | Rescues short-term and spatial memory | AD | |
100 nM and 10 µM | ≥ 1 h | HT22 and PC12 | / | / | / | ||||
Lapchak et al. 2013 [29] | 1-300 µM | 6 or 24 h | H4IIE cell line | / | / | / | Effects on cellular toxicity | CeeToxTM safety and genotoxicity analysis | |
1-300 µM | Fed for 4 days | Rat | / | / | / | ||||
Currais et al. 2015 [18] | 10 mg/kg/day | Fed for 7 months | Mice | 3–13 months | OFT, EPM, Barnes maze and object recognition | better performance | Reduces age-related RNA expression, rescues metabolomic of plasma and cortex biological pathways, decreases inflammation, and prevents alterations in Aβ and tau homeostasis | Aging and dementia | |
Kim et al. 2015 [32] | 100 µM | 7–48 h | SH-SY5Y | / | / | / | Inhibits oligomerization and fibrillation of β-amyloid peptides and protects neuronal cells from β-amyloid-induces cytotoxicity | Cytotoxicity | |
Chen et al. 2015 [33] | 20 mg/kg | / | Mice | 5–6 months | Y-maze | better performance | Induces the expression of many neurotrophic factors | AD | |
0.001 to 10 µM | 24 h | Primary cerebellar granule and cortical neurons, PC12 | / | / | / | ||||
Prior et al. 2016 [34] | 200 ppm | Fed for 6 months | Mice | 8–24 months | EPM, RI, fear conditioning, and pattern separation tests | better performance | Enhances memory, improves synaptic spine density, and stimulates neural stem and progenitor cell expansion | AD | |
| Â | / | / | HT22 and MC65 | / | / | / | Â | Â | |
Daugherty et al. 2017 [35] | 10 mg/kg/day | Fed for 3 months | Sprague–Dawley rat | 13-months | Two-day water maze, EPM, fear-conditioning assay, and OFT | better performance | Reduces inflammation, increases for neurogenesis and synapses, and modulates fatty acid metabolism | Fatty liver disease | |
10Â mg/kg/day | Fed for 3 months | Mice | 13 months | Two-day water maze, EPM, fear-conditioning assay, and OFT | better performance | ||||
6–74 nM | / | HT22, MC65, and primary cortical neurons | / | / | / | ||||
Daugherty et al. 2018 [27] | 10 mg/kg or 50 mg/kg | 24 h | Mice and rats | > 12 weeks | Paw thermal sensitivity, MNCV, Rotarod and Von Frey filaments | better performance | Anti-inflammatory and activates AMP kinase pathway | Diabetes | |
Goldberg et al. 2018 [25] | 10 mg/kg/day | Fed for 6 months | Mice | 3–10 months | / | / | Increases in intracellular calcium leading to sustained CAMKK2-dependent activation of the AMPK/mTOR pathway | Aging and dementia | |
0.1 or 2 µM | Fed for 10 days | Drosophila | 1 week | / | extends lifespan | ||||
0-1000 µM | 0–48 h | HT22, MC65 and primary cortical neurons | 15 min | / | / | ||||
Lian et al. 2018 [36] | 2, 5 and 10 mg/kg | > 1 h | Mice | Adult | TST, FST and LAT | better performance | Increases pCREB, cAMP, PKA, and BDNF levels | Depression | |
Lv et al. 2018 [21] | 10Â mg/kg/day and 100Â mg/kg/day | Fed for 5 days | Rat | Adult | Von Frey filaments | better performance | Increases AMPK expression, reduces TRPA1 expression and calcium reaction level | Diabetes | |
10 µM and 100 µM | 24 h | RSC96 cells | / | / | / | ||||
Currais et al. 2019 [18] | 10Â mg/kg/day | Fed for 4 months | Mice | 9 months & and 13 months | EPM and Barnes maze reversal | better performance | Preserves key brain mitochondrial metabolites and elevating acetyl-CoA levels reduces aspects of brain aging | Aging | |
1µM, 50 and 100 nM | 24 h | HT22 and primary neurons | / | / | / | ||||
Li et al. 2020 [31] | 1, 3 and 9Â mg/kg | Fed for 3 days | Mice | Adult | TST and FST | better performance | Modulates 5-HT1A-dependent cAMP/PKA/pCREB/BDNF | Depression | |
Goldberg et al. 2020 [37] | 10 mg/kg/day | Fed for 4 months | Mice | 9 months and 13 months | / | / | Modulates Ca2 + metabolism and against age-related neurotoxicity | AD | |
1 µM | Overnight | HT22 | / | / | / | ||||
Pan et al. 2021 [38] | 10Â mg/kg | Fed for 3 days | Mice | Adult | OFT, TST, FST, NSFT, SPT and LAT | better performance | Inhibits MAO-A activity and increases synaptic monoamines | Depression and anxiety | |
Kepchia et al. 2021 [39] | 10Â mg/kg/day | Fed for 4 months | Mice | 9 months and 13 months | EPM | better performance | Prevent age-associated disease in brain and kidney | AD | |
2 µM | 1–71 days | Drosophila | 1–71 days | / | extends lifespan | ||||
Lv et al. 2021 [22] | 1, 2 and 4 µM | 35–60 h | Zebrafish | / | / | / | ERK pathway, anti-melanosome effects, inhibits melanin production, prevents dendrite extension and melanosome distribution | Skin-whitening | |
1% | Twice a day for 3 weeks | Guinea pigs | 6 weeks | / | / | ||||
1–8 µM | 0–48 h | B16F10 murine melanocytes | / | / | / | ||||
Kepchia et al. 2022 [19] | / | Fed for 4 months | Mice and Wistar rats | 9 months and 13 | / | / | Activation of the AMPK/ACC1 pathway in the liver and decreased plasma free fatty acid levels | Fatty liver disease | |
1 µM | 24 h | HepG2 cell | / | / | / | ||||
Jin et al. 2022 [28] | 1,10 and 30Â mg/kg | 72Â h | Rat | Adult | / | better performance | Reduces tPA-induced brain hemorrhage | Stroke | |